Thursday 14 July 2016

Dishman Pharma’s Swiss and Ahmedabad unit gets EIR from USFDA; stock jumps 6%

Additionally, the company’s site at Naroda had also successfully completed USFDA Inspection and received the Establishment Inspection Report (EIR) for the same.

Dishman Pharmaceuticals
Dishman Pharmaceuticals and Chemicals informed BSE that the company's wholly owned subsidiary, namely Carbogen Amcis AG., Switzerland, had successfully completed US FDA Inspection for its two sites located at Aarau and Neuland without any adverse observations and received the Establishment Inspection Report (EIR)for the same. Thus, now the company has the above two sites in addition to Bubendorf in Switzerland, which are approved by the USFDA.

Additionally, the company’s site at Naroda had also successfully completed USFDA Inspection and received the Establishment Inspection Report (EIR) for the same.

Dishman Pharmaceuticals and Chemicals Ltd is currently trading at Rs. 140.2, up by Rs. 6.9 or 5.18% from its previous closing of Rs. 133.3 on the BSE.

The scrip opened at Rs. 132.05 and has touched a high and low of Rs. 143.4 and Rs. 131.85 respectively. So far 781511(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 2151.39 crore.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 209.85 on 04-Nov-2015 and a 52 week low of Rs. 79.78 on 20-Jul-2015. Last one week high and low of the scrip stood at Rs. 149 and Rs. 133 respectively.

The promoters holding in the company stood at 61.4 % while Institutions and Non-Institutions held 25.21 % and 13.39 % respectively.

The stock is currently trading below its 200 DMA.

No comments:

Post a Comment